Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Solid Biosciences Inc.    SLDB

SOLID BIOSCIENCES INC.

(SLDB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/25/2021 02/26/2021 03/01/2021 03/02/2021 03/03/2021 Date
8.01(c) 7.97(c) 8.52(c) 10.72(c) 9.89(c) Last
1 668 035 737 316 779 879 2 164 386 2 002 828 Volume
-13.03% -0.50% +6.90% +25.82% -7.74% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -87,8 M - -
Net cash position 2020 60,6 M - -
P/E ratio 2020 -6,01x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -109 M - -
Net cash position 2021 180 M - -
P/E ratio 2021 -8,87x
Yield 2021 -
Capitalization 651 M 651 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 121
Free-Float 49,8%
More Financials
Company
Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program,... 
Sector
Biotechnology & Medical Research
Calendar
03/11 | 09:45amPresentation
More about the company
Notations Surperformance© of Solid Biosciences Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about SOLID BIOSCIENCES INC.
02/24Efficacy and Safety Data from Solid Biosciences' Ongoing IGNITE DMD Phase I/I..
GL
02/17SOLID BIOSCIENCES  : to Present at Upcoming Investor Conferences
AQ
01/11SOLID BIOSCIENCES INC.  : Regulation FD Disclosure (form 8-K)
AQ
01/08SOLID BIOSCIENCES  : Sarepta's Mixed Results in Duchenne Muscular Dystrophy Tria..
MT
01/08SOLID BIOSCIENCES  : Credit Suisse Upgrades Solid Biosciences to Neutral from Un..
MT
01/06Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference
GL
2020INSIDER TRENDS : Solid Biosciences Insider Gets Stock Award, Prolongs Buy Trend
MT
2020INSIDER TRENDS : Solid Biosciences Insider Granted Stock Award, Extends Buy Tren..
MT
2020INSIDER TRENDS : Solid Biosciences Insider Receives Stock Award, Trend of Buys E..
MT
2020INSIDER TRENDS : Solid Biosciences Insider Gets Stock Award, Prolongs Buy Trend
MT
2020INSIDER TRENDS : Solid Biosciences Insider Gets Stock Award Retains Shares, Inte..
MT
2020MIDDAY REPORT : Wall Street Weaker Midday On Stimulus Woes
MT
2020SOLID BIOSCIENCES  : Announces $90 Million Private Share Placement; Stock Rises
MT
2020SOLID BIOSCIENCES INC.  : Entry into a Material Definitive Agreement, Unregister..
AQ
2020Solid Biosciences Announces $90 Million Private Placement
GL
More news
News in other languages on SOLID BIOSCIENCES INC.

- No features available -

More news
Analyst Recommendations on SOLID BIOSCIENCES INC.
More recommendations
Chart SOLID BIOSCIENCES INC.
Duration : Period :
Solid Biosciences Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SOLID BIOSCIENCES INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 6,70 $
Last Close Price 9,89 $
Spread / Highest target 26,4%
Spread / Average Target -32,3%
Spread / Lowest Target -79,8%
EPS Revisions
Managers and Directors
NameTitle
Ilan Ganot President, Chief Executive Officer & Director
Stephen J. DiPalma Chief Financial & Accounting Officer
Ian Frederick Smith Chairman
Carl Morris Chief Scientific Officer
Joel Schneider Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
SOLID BIOSCIENCES INC.30.47%651
GILEAD SCIENCES, INC.8.15%79 178
VERTEX PHARMACEUTICALS-11.81%55 127
WUXI APPTEC CO., LTD.8.16%53 600
REGENERON PHARMACEUTICALS-5.85%47 371
BEIGENE, LTD.17.86%28 072